4586

譬ｪ蠑丈ｼ夂､ｾ繝｡繝峨Ξ繝�繧ｯ繧ｹ

株式会社メドレックス
Pharmaceutical
MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops transdermal medicines based on the ionic liquid transdermal system (ILTS) and the nano-sized colloid transdermal system (NCTS); and microneedle arrays/patch vaccines for the delivery of vaccines and APIs through the skin. Its products also include MRX-5LBT, which has NDA approval in the United States for neuropathic pain; MRX-4TZT, which is in a Phase II trial for spastic paralysis; Alto-101, which is in a Phase II trial for schizophrenia; MRX-9FLT, which is in a Phase I trial for moderate to severe pain; and MRX-6LDT, which is in a drug formulation development stage for chronic pain. MedRx Co., Ltd was incorporated in 2002 and is headquartered in Higashikagawa, Japan.
← Companies
Price
¥65
Market Cap
¥3.9B
Ent. Value
—
Net Cash est
—
Shares Out.
59.4M
P / E
—
EV / EBIT
—
P / Book
1.94×
P / NCAV
2.25×
Div. Yield
—
Financials
Metric FY 2025
EDINET ↗ 		FY 2024
EDINET ↗ 		FY 2023
EDINET ↗ 		FY 2022
EDINET ↗ 		FY 2021
EDINET ↗
Net Sales ¥128M ¥258M ¥30M ¥59M ¥8M
Cost of Sales ¥1M ¥0M ¥2M ¥3M ¥2M
Gross Profit ¥127M ¥258M ¥27M ¥57M ¥6M
SG&A ¥1.1B ¥1.1B ¥961M ¥1.2B ¥1.1B
Operating Income ¥-942M ¥-793M ¥-934M ¥-1.1B ¥-1.1B
Non-Operating Income ¥20M ¥53M ¥14M ¥1M ¥2M
Interest Income ¥3M ¥0M ¥0M ¥0M ¥0M
Non-Operating Expenses ¥16M ¥15M ¥12M ¥15M ¥15M
Interest Expense — — — — ¥1M
Ordinary Income ¥-937M ¥-755M ¥-931M ¥-1.1B ¥-1.1B
Pre-tax Income ¥-925M ¥-803M ¥-930M ¥-1.1B ¥-1.1B
Income Taxes ¥12M ¥4M ¥3M ¥2M ¥1M
Current Tax ¥12M ¥9M ¥3M ¥2M ¥2M
Deferred Tax — ¥-5M ¥-0M ¥-0M ¥-0M
Net Income (owners) ¥-937M ¥-807M ¥-933M ¥-1.1B ¥-1.1B
Comprehensive Income ¥-866M ¥-810M ¥-931M ¥-1.1B ¥-1.1B
EBITDA ¥-928M ¥-755M ¥-888M ¥-1.1B ¥-1.0B
EPS ¥-17.44 ¥-18.56 ¥-26.82 ¥-43.81 ¥-49.62
Shares Outstanding 59.4M 47.5M 38.4M 28.2M 24.6M
Shares Issued (total) 59.4M 47.5M 38.4M 28.2M 24.6M